Thomas Helleday
Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors.
Overview
Thomas Helleday's laboratory published, back-to-back with Alan Ashworth's, the 2005 Nature paper showing that BRCA2-deficient cells are exquisitely sensitive to PARP inhibition, the discovery that led to olaparib, niraparib, rucaparib and talazoparib and established synthetic lethality as a drug-discovery strategy. He later developed the MTH1 inhibitor concept and continues to work on DNA repair targets.
| Title | Journal | Year |
|---|---|---|
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Nature | 2005 |
| The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings | Molecular Oncology | 2011 |
Pages like this
not linked directly; found by shared links- PersonJonathan A. Ledermann
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD) and the tag parp.
- PersonAlan D. D'Andrea
Shares Synthetic lethality approaches, PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD) and the tag parp.
- PersonAlan Ashworth
Shares Synthetic lethality approaches, PARP inhibitors, Olaparib, PARP.
- PersonTalia Golan
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD) and the tag parp.
- PersonMaha Hussain
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD) and the tag parp.
- PersonChristopher Lord
Shares Synthetic lethality approaches, PARP inhibitors, PARP, BRCA1 / BRCA2 (HRD).
- PersonIsabelle Ray-Coquard
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD) and the tag parp.
- TrialSOLO-1
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).